Regentatlantic Capital LLC Tg Therapeutics, Inc. Transaction History
Regentatlantic Capital LLC
- $3.34 Billion
- Q3 2022
Shares
2 transactions
Others Institutions Holding TGTX
# of Institutions
335Shares Held
87.6MCall Options Held
2.35MPut Options Held
1.7M-
Vanguard Group Inc Valley Forge, PA15.4MShares$448 Million0.01% of portfolio
-
Black Rock Inc. New York, NY11.4MShares$332 Million0.0% of portfolio
-
State Street Corp Boston, MA9.09MShares$265 Million0.01% of portfolio
-
Pictet Asset Management Holding Sa Carouge, V83.58MShares$104 Million0.1% of portfolio
-
Geode Capital Management, LLC Boston, MA3.21MShares$93.4 Million0.01% of portfolio
About TG THERAPEUTICS, INC.
- Ticker TGTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 145,274,000
- Market Cap $4.23B
- Description
- TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hod...